Multiple tools have been developed to block IL-1β activity: the recombinant IL-1Ra Anakinra used for rheumatoid arthritis, the neutralizing IL-1β antibody Canakinumab used for systemic juvenile idiopathic arthritis as well as cryopyrin-associated periodic syndrome, and the soluble decoy IL-1 receptor (Rilonacept) also use for cryopyrin-associated periodic syndromes (153). Here, IL1B is linked to rheumatoid arthritis.